Company news
Futura Medical Plc (LSE:FUM) news
Futura Medical Plc news releases on 6ix. Latest, Jan 17, 2020: GM Statement
Press releases — page 4
GM Statement
January 17, 2020
Result of Fundraising
December 23, 2019
PrimaryBid Offer
December 20, 2019
Top Line Results from MED2005 Phase 3 study
December 10, 2019
Publishes Fireside Chat with Prof Wayne Hellstrom
November 14, 2019
MED2005 Safety and Efficacy Data Reported at SMSNA
October 28, 2019
Change of Auditor
October 23, 2019
Final Dosing of Last Patient in MED2005 Ph3 study
October 21, 2019
Futura Medical to Present Data on MED2005 at SMSNA
October 15, 2019
Interim Results for Six Months ended 30 June 2019
September 11, 2019
Futura Announces Joint Venture Collaboration
September 10, 2019
Recruitment completed for MED2005 Phase 3 study
June 19, 2019
Notice of AGM
May 30, 2019
Liberum Appointed as Nominated Adviser & Broker
May 23, 2019
Preliminary Results for the year ended 31 Dec 2018
April 10, 2019
Notice of Preliminary Results
March 5, 2019
Futura to host EU Advisory Panel Meeting at ESSM
February 14, 2019
Presentation at the 21st ESSM Congress
January 28, 2019
Futura Medical to Host R&D Day in February 2019
December 17, 2018
Block listing update
November 30, 2018
Application for Block Listing
November 26, 2018
Director/PDMR Dealings
November 13, 2018
Result: Open Offer General Meeting & Voting Rights
November 12, 2018
Presents Data on MED2005 at SMSNA Annual Meeting
November 9, 2018
1st Patient Enrolled in European Ph3 MED2002 study
October 31, 2018
Further Details on the Fundraising
October 19, 2018
Offer on PrimaryBid.com
October 18, 2018
Interim Results for the Six Months 30 June 2018
September 26, 2018
Business Update
September 19, 2018
TPR 100: UK Regulatory Submission
July 23, 2018
Block Listing Interim Review
May 30, 2018
Notification of Major Interest in Shares
April 27, 2018
Phase III efficacy study of MED2002
April 26, 2018
Positive data from MED2002 PK study
April 25, 2018
Preliminary Results
March 14, 2018
Positive Interim Data from MED2002 PK study
March 13, 2018
Directorate Changes
February 20, 2018
Notification of Preliminary Results
February 15, 2018
Publication of Positive MED2002 Clinical Data
January 4, 2018
MED2002: PK Study Commences
November 29, 2017
Block Listing Update
November 24, 2017
PDMR Dealing
October 23, 2017
Further Positive Market Research Data for MED2002
October 16, 2017
Interim Results
September 12, 2017
CSD500: Termination of Licensing Agreement
August 23, 2017
Notification of Half Year Results
August 22, 2017
Investor Presentation on MED2002
July 4, 2017
MED2002 Regulatory Update
May 31, 2017
Licenses CSD500 in Portugal
March 22, 2017
MED2002 Additional Patent Filing
March 6, 2017